Medimaging Integrated Solution Inc. (MiiS; 晉弘科技; 6471 TT) announced that its innovative micro-invasive diagnostic device, the EJA100 Electronic Arthroscope, has officially secured its Class II Medical Device Marketing Authorization from the Taiwan FDA (TFDA). Following its previous US FDA 510(k) clearance, this milestone completes the company's dual-platform layout across both rigid and flexible single-use endoscopic surgical sectors.

• The Rigid and Flexible Portfolio Matrix: MiiS has structured a complete micro-invasive diagnostic portfolio via a unified development platform:
• Rigid Arthroscope Systems: Engineered to enter high-barrier orthopedics and sports medicine surgical sectors, capturing premium, technically demanding clinical segments.
• Flexible Endoscope Systems: Deployed across urology, otolaryngology (ENT), and respiratory care units to maximize market penetration and institutional footprint coverage.
• AI Diagnostics Integration: MiiS emphasized that next-generation endoscopic competition centers on appending digital medicine and AI algorithms to native video streams to drive clinical efficiency. The company is actively funding AI medical imaging analysis, localized digital health data repositories, and portable diagnostic consoles to build smart, integrated micro-invasive clinical systems linked to tele-health platforms.
• Post-Pandemic Infection Control Demands: Single-use endoscopes eliminate cross-infection risks, negate hospital sterilization overheads, and streamline clinical throughput. According to global healthcare market datasets, the single-use endoscope market is growing at a compound annual growth rate (CAGR) exceeding 20%, expanding from traditional airway paths into complex orthopedic and arthroscopic micro-surgeries.
• Financial Outlook and Recovery Guidance: MiiS’s Q1 financial performance was impacted by near-term product mix recalibrations, putting temporary pressure on gross margins and resulting in a net loss per share (EPS) of -NT$0.32. However, management expects commercial momentum to accelerate significantly as its rigid and flexible endoscope portfolios clear multi-national regulatory hurdles and enter the supply chains of tier-one global distributors. The company targets a return to double-digit top-line growth, positioning its revenue architecture and gross margins to return to historical peaks.

Resource:晉弘關節鏡獲台上市許可，雙軌布局完成，業績拚返高峰